Dr. April A. Erwin, MD
Neurology (Neurology Physician)
370 E 9th Ave Ste 106
Salt Lake City, UT 84103
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 211
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Louisiana State University School of Medicine in New Orleans
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
LA license MD.205310 -
Internal Medicine Physician
DC license MD037611
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Medical Center Murray, UT
- St. George Regional Hospital St George, UT
- Intermountain Health Mckay-Dee Hospital Ogden, UT
- Lds Hospital Salt Lake City, UT
- Intermountain Health Logan Regional Hospital Logan, UT
Medical groups
- Dr John Foley LLC (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 211
- Services billed
- 77,102
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Injection, natalizumab, 1 mg | 50,718 | 81 |
| Injection, ocrelizumab, 1 mg | 5,403 | 13 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 182 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 148 | 125 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 79 | 22 |
| Injection of additional new drug or substance into vein | 34 | 23 |
| Administration of chemotherapy into vein, each additional hour | 31 | 15 |
| Administration of chemotherapy into vein, 1 hour or less | 29 | 25 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 26 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Salt Lake City, UT | 152 |
| Gabapentin Other prescribers in Salt Lake City, UT | 150 |
| Dalfampridine Er (dalfampridine) | 56 |
| Modafinil Other prescribers in Salt Lake City, UT | 52 |
| Pregabalin Other prescribers in Salt Lake City, UT | 50 |
| Diazepam Other prescribers in Salt Lake City, UT | 45 |
| Memantine Hcl Other prescribers in Salt Lake City, UT | 40 |
| Dimethyl Fumarate | 36 |
| Dantrolene Sodium | 35 |
| Lamotrigine Other prescribers in Salt Lake City, UT | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 214 payments worth $33,138 in total to this clinician.
| Genzyme Corporation | $10,290 |
|---|---|
| Novartis Pharmaceuticals Corporation | $6,887 |
| Genentech USA, Inc. | $6,819 |
| EMD Serono, Inc. | $5,151 |
| Tg Therapeutics, Inc. | $1,719 |
| Biogen, Inc. | $498 |
| AbbVie Inc. | $498 |
| UCB, Inc. | $161 |
| Consulting Fee | $27,278 |
|---|---|
| Food and Beverage | $4,427 |
| Travel and Lodging | $1,434 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $10,215 |
| Genentech USA, Inc. Jun 20, 2025 | Consulting Fee | $5,800 |
| Novartis Pharmaceuticals Corporation May 9, 2025 | Consulting Fee KESIMPTA · Neurology | $5,300 |
| EMD Serono, Inc. Jan 16, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $2,400 |
| EMD Serono, Inc. Nov 25, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,200 |
| EMD Serono, Inc. Jul 18, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,200 |
| Tg Therapeutics, Inc. Jun 20, 2025 | Consulting Fee BRIUMVI · Immunology | $1,013 |
| Novartis Pharmaceuticals Corporation May 8, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to Rosemont, IL · in-kind | $738 |
| Genentech USA, Inc. Jun 20, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $278 |
| Novartis Pharmaceuticals Corporation May 9, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to ROSEMONT, IL · in-kind | $188 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. Nov 25, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,200 |
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $10,215 |
| EMD Serono, Inc. Jul 18, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $1,200 |
| Genentech USA, Inc. Jun 20, 2025 | Consulting Fee | $5,800 |
| Tg Therapeutics, Inc. Jun 20, 2025 | Consulting Fee BRIUMVI · Immunology | $1,013 |
| Genentech USA, Inc. Jun 20, 2025 | Travel and Lodging travel to Dallas, TX · in-kind | $278 |
| Genentech USA, Inc. Jun 20, 2025 | Travel and Lodging travel to Dallas, TX | $171 |
| Biogen, Inc. May 26, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Novartis Pharmaceuticals Corporation May 9, 2025 | Consulting Fee KESIMPTA · Neurology | $5,300 |
| Novartis Pharmaceuticals Corporation May 9, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to ROSEMONT, IL · in-kind | $188 |
| Novartis Pharmaceuticals Corporation May 9, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to ROSEMONT, IL | $58.06 |
| Novartis Pharmaceuticals Corporation May 8, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to Rosemont, IL · in-kind | $738 |
| EMD Serono, Inc. Jan 16, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $15,873 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab
Tg Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.